Abivax (ABVX) has granted AstraZeneca (AZN) an exclusive period through March 23 to access confidential information and formalize a potential takeover offer, La Lettre’s Matthew Protard reports. After that date, Abivax may reopen discussions with other interested bidders if no deal is reached, Protard writes.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca granted exclusive period by Abivax for buyout, La Lettre reports
- AstraZeneca: Late‑Stage Pipeline Strength, Margin Expansion, and Undervalued Earnings Inflection Justify Buy Rating
- AstraZeneca Wraps Real-World Lung Cancer Study, Sharpening Market Insight for AZN Investors
- AstraZeneca Completes Key Japan Safety Study for Imfinzi/Imjudo in Liver Cancer
- AstraZeneca Sets Digitally Enabled 2026 AGM with Key Governance and Capital Votes